McKee, Ph.D., a 2004 BBRF Young Investigator, recruited 48 participants at the University of North Carolina, Chapel Hill, for their phase 2 trial (such trials are typically small and are geared to determine if there is strong reason to test a therapy in a larger populationtypically at much greater expense and effort)
Veru aims to define an adjunct category, not compete with incretins, by protecting muscle, supporting bone health, and improving physical function
doi: 10.4162/nrp.2025.19.4.554
This distinction matters because treatments targeting inflammation alone may provide only temporary relief without addressing the underlying tissue damage
($1 = C$1.30927)
If the peptide you start with isn't pure, no amount of perfect technique can save your research